Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARC1779 in Carotid Endarterectomy
NCT00742612Phase 2Terminated
- Sponsor
- Archemix Corp.
- Start
- Feb 2009
- Primary completion
- Jan 2010
- Modality
- RNA Aptamers, Recombinant Proteins and Enzymes, DNA Aptamers
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in cerebral microembolism and cerebral sinovenous thrombosis (CSVT) comparing ARC1779 with Placebo (2 arms). Primary endpoints: Number of microembolic signals detected by transcranial Doppler (TCD) and Safety of ARC1779 Injection with respect to bleeding risk. Started Feb 2009; status: terminated.
02
Drugs
egaptivon pegol
03
Conditions
cerebral microembolismcerebral sinovenous thrombosis (CSVT)
Beyond the preview
Go deeper on NCT00742612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00742612.